Cell-Based Vital Organs Specific Biomarkers Assessment using Biofield Energy Based Novel Test Formulation

Journal: Journal of Biotechnology and Biomedical Science PDF  Web

Published: 10-Jul-19 Volume: 2 Issue: 1

DOI: 10.14302/issn.2576-6694.jbbs-19-2944 ISSN: 2576-6694

Authors: Janice Patricia Kinney, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana

Citation: Janice Patricia Kinney, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak et al. (2019) Cell-Based Vital Organs Specific Biomarkers Assessment using Biofield Energy Based Novel Test Formulation. Journal of Biotechnology and Biomedical Science - 2(1):31-45.

  • 7 Views
  • Downloads

Abstract

The aim of the present study was to determine the impact of Biofield Energy Treated test formulation using six different cell-lines. The test formulation/item (TI) and cell media (Med) was divided into two parts; one part was untreated (UT) and other part received Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Janice Patricia Kinney, USA and labeled as Biofield Energy Treated (BT) test item (TI)/media. Based on cell viability assay, test formulation was found as safe at tested concentrations. Cytoprotective activity of test formulation showed a significant restoration of cell viability by 60.6% (10 μg/mL), 67.5% (63.75 μg/mL), and 117.5% (63.75 μg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI, respectively compared to untreated in human cardiac fibroblasts cells (HCF) cells. Moreover, restoration of cell viability was improved by 64% and 127.3% in UT-Med + BT-TI and BT-Med + UT-TI, respectively at 1 μg/mL compared to untreated in human liver cancer (HepG2) cells. Cellular restoration in A549 cells was improved by 314% and 112.3% at 1 μg/mL in BT-Med + UT-TI and BT-Med + BT-TI, respectively than untreated. ALP activity in Ishikawa cells was significantly increased by 175.5%, 547.2%, and 220.8% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 0.1 μg/mL as compared to untreated. Additionally, in MG-63 cells showed increased ALP activity by 76.9%, 78.4%, and 79% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 50 μg/mL compared to untreated. The percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 60.6% (10 μg/mL), 67.5% (63.75 μg/mL), and 117.5% (63.75 μg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively as compared to untreated. An improved HepG2 cells protection (represents decreased ALT activity) by 115.1% (1 μg/mL), 42.5% (25.5 μg/mL), and 60.8% (10 μg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI, respectively as compared to untreated. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was significantly increased by 191.1% and 81.4% at 0.1 μg/mL in UT-Med + BT-TI and BT-Med + BT-TI, respectively as compared to untreated. Serotonin level was significantly increased by 31.8% (10 μg/mL) and 56.9% (25.5 μg/mL) in UT-Med + BT-TI and BT-Med + BT-TI, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). Relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 304.3% (0.01 μg/mL), 128.4% (0.1 μg/mL), and 240% (0.1 μg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively compared to untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) significantly improved organ specific functional biomarkers and would be useful for multiple organs health related to coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

Cell viability (using MTT assay) data showed the test formulation was found safe and non-toxic against all the tested cell-lines. Cytoprotective activity against t-BHP induced cell damage was tested using human cardiac fibroblasts cells (HCF), which showed restoration of cell viability by 60.6% (10 µg/mL), 67.5% (63.75 µg/mL), and 117.5% (63.75 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated. In HepG2 cells, the restoration of cell viability was observed as 64% and 10% at 1 and 63.75 µg/mL, respectively in the UT-Med + BT-TI group; however, 127.3%, 41.2%, and 16.6% improved cellular restoration at 1, 10, and 25 µg/mL, respectively in the BT-Med + UT-TI group as compared to the untreated group. Moreover, 33.3%, 28.4%, and 30.4% improved cellular restoration at 1, 10, and 25.5 µg/mL, respectively in the BT-Med + BT-TI group as compared to the untreated group. In A549 cells, cellular restoration was improved by 605.3% at 1 µg/mL in the UT-Med + BT-TI group; while, 314% and 12.5% at 1 and 10 µg/mL, respectively in the BT-Med + UT-TI group as compared to the untreated group. Moreover, 112.3%, 6.5%, and 4.1% improved cellular restoration was reported at 1, 10, and 25.5 µg/mL, respectively at BT-Med + BT-TI group as compared to the untreated test group. Similarly, ALP activity in Ishikawa cells showed significantly increased ALP activity by 175.5%, 547.2%, and 220.8% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1 µg/mL as compared to the UT-Med + UT-TI group. Similarly, ALP activity in MG-63 cells the cellular protection was reported by 76.9%, 78.4%, and 79% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL as compared with the untreated group. The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 60.6% (10 µg/mL), 67.5% (63.75 µg/mL), and 117.5% (63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated group. ALT activity showed an improved cellular protection of HepG2 cells (decreased of ALT activity) by 115.1% (1 µg/mL), 42.5% (25.5 µg/mL), and 60.8% (10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared with the untreated group. SOD activity was significantly increased by 191.1%, 34.5%, and 81.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1 µg/mL as compared with the untreated group. Serotonin level was significantly increased in SH-SY5Y cells by 31.8% (10 µg/mL), 18.3% (10 µg/mL), and 56.9% (25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared with the untreated group. However, VDR expression was tested in MG-63 cells, which showed an increased RQ of VDR by 304.3%, 277.7%, and 229.4% at 0.01, 0.1, and 1 µg/mL, respectively in the UT-Med + BT-TI group; while, 40.3%, 128.4%, and 86.4% increased RQ of VDR at 0.01, 0.1, and 1 µg/mL, respectively in the BT-Med + UT-TI group as compared to the untreated group. Moreover, 240% and 221.8% increased RQ of VDR at 0.1 and 1 µg/mL, respectively in the BT-Med + BT-TI group as compared to the untreated group. Thus, this study concluded that the Biofield Energy based test formulation can improve the overall functioning of heart, liver, bones, neuronal, and lungs parameters against any oxidative stress or damage induced by free radicals. Biofield Energy Treatment (The Trivedi Effect®) can be used for the prevention of various types of cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Besides, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, and Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Asthma, Aplastic Anemia, Graves’ Disease, Dermatitis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Ulcerative Colitis (UC), Atherosclerosis, etc. to improve overall health and Quality of Life.